Posts in Category: News

Helium Special Situations increases interest in Scancell

Scancell Holdings Plc

(‘Scancell Holdings’ or the ‘Company’)

Holdings in Company

The Company announces that it has received notification that Helium Special Situations Fund Limited has increased its beneficial interest in Scancell Holdings to 17,586,940 ordinary shares of 0.1 pence each which represents approximately 9.06 per cent of the issued capital of the Company.

For further information contact:

Scancell Holdings Plc 

Professor Lindy Durrant/Dr Richard Goodfellow

+ 44 (0)207 245 1100

Hansard Communications- Financial PR 

Adam Reynolds/Guy McDougall

+ 44 (0)207 245 1100

Zeus Capital - Nominated Adviser

Ross Andrews/Tom Rowley

+ 44 (0)161 831 1512

XCAP Securities Plc - Broker

Jon Belliss/ Adrian Kirk

+44 (0) 207 101 7070

Confirmation of second tranche payment of £2.85 million from Arana Therapeutics

Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer vaccines, is pleased to announce that it has received confirmation from Cephalon, Inc that the condition relating to the second tranche payment from the sale of Scancell’s antibody portfolio to Arana Therapeutics in 2006 has now been satisfied. Scancell is therefore due to receive a further sum of £2.85 million (before any related tax and other costs are deducted) on 16 November 2011.

Background

On 1 December 2006, Scancell sold its portfolio of antibodies to Arana Therapeutics (then known as Peptech (UK) Limited and subsequently acquired by Cephalon, Inc, which itself is now owned by Teva Pharmaceutical Industries Limited). The consideration for the sale was a cash payment of £2 million, which was paid on completion of the sale, plus a possible further sum of £2.85 million gross which was payable when a milestone was achieved relating to the development of a drug derived from any of the antibodies which were the subject of the sale.

Confirmation that payment is due

Scancell has received confirmation from Cephalon, Inc that this milestone has been achieved and the condition for payment of the further sum of £2.85 million has therefore been satisfied.

The receipt of the second tranche payment is expected to trigger a payment to advisers of the Company and, under an executive incentivisation package agreed by the Board in June 2006, Professor Lindy Durrant, Dr Richard Goodfellow and Nigel Evans are entitled to receive gross bonuses calculated as a percentage of the net payment received by the Company. The total of these payments is not expected to exceed £450,000.

The £2.85 million gross proceeds from the second tranche payment will therefore be reduced by the payment of bonuses and adviser costs as noted above and does not take into account any corporation tax that may arise.

David Evans, Chairman of Scancell, said: "The confirmation that Scancell will receive the second tranche payment of £2.85 million from Arana Therapeutics is excellent news for the Company. We expect that the net funds to be received will enable the Company to complete the Phase I and Phase II clinical trials of our lead melanoma vaccine, SCIB1, without the need to raise further funds from Shareholders."

For further information contact:

Scancell Holdings Plc
Dr Richard Goodfellow / Professor Lindy Durrant
+44 (0)207 245 1100*

Hansard Group (Financial PR)
Adam Reynolds / Guy McDougall
+44 (0)207 245 1100

Zeus Capital - Nominated Adviser/Joint Broker
Ross Andrews / Tom Rowley
+44 (0)161 831 1512

XCAP - Joint Broker
John Belliss / Adrian Kirk
+44 (0) 207 101 7070

*this number will direct callers to Hansard Group, at Scancell's instruction.

About Scancell

Scancell is developing novel therapeutic vaccines for the treatment of cancer and infectious diseases based on its groundbreaking ImmunoBody® technology platform. Scancell’s first cancer vaccine SCIB1, which entered clinical trials in 2010, is being developed for the treatment of melanoma.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be administered to a patient, stimulating an immune response. Effective cancer vaccines need to target dendritic cells to stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they cannot specifically target dendritic cells in vivo. Several groups have demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing them with tumour antigens and re-infusing them. However, this procedure is patient specific, time consuming and expensive. Scancell has developed its breakthrough patent protected ImmunoBody® technology to overcome these limitations.

An ImmunoBody® is a human antibody or fusion protein engineered to express helper cell and CTL epitopes from tumour antigens over-expressed by cancer cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour antigens as they have long half-lives and can effectively target dendritic cells via their Fc receptors, allowing efficient stimulation of both helper and CTL responses.

The Immunobody® technology can be adapted to provide the basis for treating any tumour type and may also be of potential utility in the development of vaccines against hepatitis, HIV and other chronic infectious diseases.

Progress on possible second tranche payment from Arana Therapeutics

Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer vaccines, is pleased to provide shareholders with an update on progress towards meeting the trigger for the second tranche payment from the sale of Scancell’s antibody portfolio to Arana Therapeutics in 2006.

On 1 December 2006, Scancell sold its portfolio of antibodies to Arana Therapeutics (then known as Peptech (UK) Limited and subsequently acquired by Cephalon Inc). The consideration for the sale was a cash payment of £2 million, which was paid on completion of the sale, plus a possible further sum of £2.85 million gross which is payable when the first patient is treated with a drug derived from any of the antibodies which were the subject of the sale, provided that this occurs prior to 6 December 2011.

A notification has recently appeared on ClinicalTrials.gov, a service of the US National Institutes of Health, confirming that a Phase 1 Study of CEP-37250 (formerly known as Scancell antibody SC104) in patients with advanced solid tumours is expected to commence in October 2011 in three US clinics.

The Phase 1 study has not yet commenced and there is no guarantee that it will commence in time to satisfy the milestone; it therefore cannot be assumed that the contingent consideration will be paid. Shareholders will be kept fully updated with any further developments.

For further information contact:

Scancell Holdings Plc
Professor Lindy Durrant
+44 (0)207 245 1100*

Hansard Group (Financial PR)
Adam Reynolds/Guy McDougall
+44 (0)207 245 1100

Zeus Capital - Nominated Adviser/Joint Broker
Ross Andrews/Tom Rowley
+44 (0)161 831 1512

XCAP - Joint Broker
John Belliss/Adrian Kirk
+44 (0) 207 101 7070

*this number will direct callers to Hansard Group, at Scancell's instruction.

About Scancell

Scancell is developing novel therapeutic vaccines for the treatment of cancer and infectious diseases based on its groundbreaking ImmunoBody® technology platform. Scancell’s first cancer vaccine SCIB1, which entered clinical trials in 2010, is being developed for the treatment of melanoma.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be administered to a patient, stimulating an immune response. Effective cancer vaccines need to target dendritic cells to stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they cannot specifically target dendritic cells in vivo. Several groups have demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing them with tumour antigens and re-infusing them. However, this procedure is patient specific, time consuming and expensive. Scancell has developed its breakthrough patent protected ImmunoBody® technology to overcome these limitations.

An ImmunoBody® is a human antibody or fusion protein engineered to express helper cell and CTL epitopes from tumour antigens over-expressed by cancer cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour antigens as they have long half-lives and can effectively target dendritic cells via their Fc receptors, allowing efficient stimulation of both helper and CTL responses.

The Immunobody® technology can be adapted to provide the basis for treating any tumour type and may also be of potential utility in the development of vaccines against hepatitis, HIV and other chronic infectious diseases.

SCIB1: Patent Awarded

Scancell Holdings plc, (AIM: SCLP), the developer of therapeutic cancer vaccines, announces that a composition of matter patent (European Patent number 2193803) has been granted for the Company’s lead vaccine, SCIB1. SCIB1 is being developed for the treatment of melanoma and is currently in Phase I clinical trials. It is an innovative DNA vaccine being developed using Scancell’s ImmunoBody® technology. This patent will protect the unique composition of the vaccine until March 2028.

Dr. Richard Goodfellow, Joint Chief Executive of Scancell, commented:

“This patent grant is a further important step in the development and commercialisation of SCIB1. Scancell will continue building its growing portfolio of intellectual property in parallel with driving the clinical trial programme forward during 2012”.

For further information contact:

Scancell Holdings Plc
Professor Lindy Durrant/Dr Richard Goodfellow
+44 (0)207 245 1100*

Hansard Group (Financial PR)
Adam Reynolds/Guy McDougall
+44 (0)207 245 1100

Zeus Capital - Nominated Adviser
Ross Andrews/Tom Rowley
+44 (0)161 831 1512

XCAP Securities Plc - Broker
John Belliss/Adrian Kirk
+44 (0) 207 101 7070

*this number will direct callers to Hansard Group, at the Company’s request.

About Scancell

Scancell is developing novel therapeutic vaccines for the treatment of cancer and infectious diseases based on its groundbreaking ImmunoBody® technology platform. Scancell’s first cancer vaccine SCIB1, which entered clinical trials in 2010, is being developed for the treatment of melanoma.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be administered to a patient, stimulating an immune response. Effective cancer vaccines need to target dendritic cells to stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they cannot specifically target dendritic cells in vivo. Several groups have demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing them with tumour antigens and re-infusing them. However, this procedure is patient specific, time consuming and expensive. Scancell has developed its breakthrough patent protected ImmunoBody® technology to overcome these limitations.

An ImmunoBody® is a human antibody or fusion protein engineered to express helper cell and CTL epitopes from tumour antigens over-expressed by cancer cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour antigens as they have long half-lives and can effectively target dendritic cells via their Fc receptors, allowing efficient stimulation of both helper and CTL responses.

The Immunobody® technology can be adapted to provide the basis for treating any tumour type and may also be of potential utility in the development of vaccines against hepatitis, HIV and other chronic infectious diseases.

Holdings in Company

The Company announces that it has received notification that Helium Special Situations Fund Limited has a beneficial interest in 15,841,940 ordinary shares of 0.1 pence each which represents approximately 8.16 per cent. of the issued capital of the Company.

For further information contact:

Scancell Holdings Plc
Professor Lindy Durrant/Dr Richard Goodfellow
+ 44 (0)207 245 1100

Hansard Communications- Financial PR
Adam Reynolds/Guy McDougall
+ 44 (0)207 245 1100

Zeus Capital - Nominated Adviser
Ross Andrews/Tom Rowley
+ 44 (0)161 831 1512

XCAP Securities Plc - Broker
Jon Belliss/Parimal Kumar
+44 (0) 207 101 7070

About Scancell

Scancell is developing novel therapeutic vaccines for the treatment of cancer and infectious diseases based on its groundbreaking ImmunoBody® technology platform. Scancell’s first cancer vaccine SCIB1, which entered clinical trials in 2010, is being developed for the treatment of melanoma.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be administered to a patient, stimulating an immune response. Effective cancer vaccines need to target dendritic cells to stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they cannot specifically target dendritic cells in vivo. Several groups have demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing them with tumour antigens and re-infusing them. However, this procedure is patient specific, time consuming and expensive. Scancell has developed its breakthrough patent protected ImmunoBody® technology to overcome these limitations.

An ImmunoBody® is a human antibody or fusion protein engineered to express helper cell and CTL epitopes from tumour antigens over-expressed by cancer cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour antigens as they have long half-lives and can effectively target dendritic cells via their Fc receptors, allowing efficient stimulation of both helper and CTL responses.

The Immunobody® technology can be adapted to provide the basis for treating any tumour type and may also be of potential utility in the development of vaccines against hepatitis, HIV and other chronic infectious diseases.

Appointment of Director

Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer vaccines, is pleased to announce the appointment of Katherine Cornish-Bowden as a non-executive director with immediate effect.

Kate (44) is a Chartered Financial Analyst and holds a Masters in Business Administration. She was managing director and head of Morgan Stanley Investment Management’s Global Core Equity Team between 2002 and 2004. Prior to this she was an executive director and senior portfolio manager within the same team at Morgan Stanley. More recently Kate has acted as a consultant providing financial research to private equity and financial training firms and was appointed a director of Investec Structured Products Calculus VCT plc in February 2011.

Kate was formerly a director of KCB Research Limited which was voluntarily removed from the Register of Companies on 12 August 2009.

There are no other requirements to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.

David Evans commented "I very much welcome Kate onto Scancell's Board, we are fortunate to have been able to attract someone of Kate's calibre and she will make an invaluable contribution to the Scancell Board going forward."

For further information contact:

Scancell Holdings Plc
Professor Lindy Durrant/Dr Richard Goodfellow
+ 44 (0)207 245 1100

Hansard Communications- Financial PR
Adam Reynolds/Guy McDougall
+ 44 (0)207 245 1100

Zeus Capital - Nominated Adviser
Ross Andrews/Tom Rowley
+ 44 (0)161 831 1512

XCAP Securities Plc - Broker
Jon Belliss/Parimal Kumar
+44 (0) 207 101 7070

About Scancell

Scancell is developing novel therapeutic vaccines for the treatment of cancer and infectious diseases based on its groundbreaking ImmunoBody® technology platform. Scancell’s first cancer vaccine SCIB1, which entered clinical trials in 2010, is being developed for the treatment of melanoma.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be administered to a patient, stimulating an immune response. Effective cancer vaccines need to target dendritic cells to stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they cannot specifically target dendritic cells in vivo. Several groups have demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing them with tumour antigens and re-infusing them. However, this procedure is patient specific, time consuming and expensive. Scancell has developed its breakthrough patent protected ImmunoBody® technology to overcome these limitations.

An ImmunoBody® is a human antibody or fusion protein engineered to express helper cell and CTL epitopes from tumour antigens over-expressed by cancer cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour antigens as they have long half-lives and can effectively target dendritic cells via their Fc receptors, allowing efficient stimulation of both helper and CTL responses.

The Immunobody® technology can be adapted to provide the basis for treating any tumour type and may also be of potential utility in the development of vaccines against hepatitis, HIV and other chronic infectious diseases.

SCIB1: Safety Review and Dose Escalation

Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer vaccines, is pleased to announce that the  second group of patients receiving the 2mg dose of SCIB1 (its DNA ImmunoBody® vaccine being developed for the treatment of melanoma) in the Phase I clinical trial has been evaluated by the Cohort Review Committee.

Following review of the safety data from this mid-dose level group of three patients, the Cohort Review Committee has approved further escalation of the dose to 4mg and recruitment of the final group of patients as planned. 

The trial, which commenced in June 2010, is designed to evaluate the safety and tolerability of SCIB1 in patients with late stage melanoma and also to gather data on the effects of SCIB1 on tumour growth and cellular immune response. 

Professor Lindy Durrant, Joint CEO of Scancell Holdings and Professor of Cancer Immunotherapy at Nottingham University, commented: “We are pleased that the Cohort Review Committee has given us the go-ahead to escalate the dose of SCIB1 to the highest dose level. This data, combined with the recent recruitment of a fifth trial centre at Southampton demonstrates that we are continuing to make good progress in our Phase 1 study. We expect to commence the Phase 2 study in late 2011/early 2012 as planned.”

For further information contact:

Scancell Holdings Plc
Professor Lindy Durrant/Dr Richard Goodfellow
+ 44 (0)207 245 1100
   
Hansard Communications
Adam Reynolds/Guy McDougall
+ 44 (0)207 245 1100
   
Zeus Capital - Nominated Adviser
Ross Andrews/Tom Rowley
+ 44 (0)161 831 1512

XCAP Securities Plc - Broker
Jon Belliss/Parimal Kumar
+44 (0) 207 101 7070About Scancell

About Scancell

Scancell is developing novel therapeutic vaccines for the treatment of cancer and infectious diseases based on its groundbreaking ImmunoBody® technology platform. Scancell’s first cancer vaccine SCIB1, which entered clinical trials in 2010, is being developed for the treatment of melanoma.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be administered to a patient, stimulating an immune response. Effective cancer vaccines need to target dendritic cells to stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they cannot specifically target dendritic cells in vivo. Several groups have demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing them with tumour antigens and re-infusing them. However, this procedure is patient specific, time consuming and expensive. Scancell has developed its breakthrough patent protected ImmunoBody® technology to overcome these limitations.

An ImmunoBody® is a human antibody or fusion protein engineered to express helper cell and CTL epitopes from tumour antigens over-expressed by cancer cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour antigens as they have long half-lives and can effectively target dendritic cells via their Fc receptors, allowing efficient stimulation of both helper and CTL responses.

The Immunobody® technology can be adapted to provide the basis for treating any tumour type and may also be of potential utility in the development of vaccines against hepatitis, HIV and other chronic infectious diseases.

Result of AGM and General Meeting

Scancell Holdings plc, (‘Scancell’ or the ‘Company’) the developer of therapeutic cancer vaccines, is pleased to announce the following:

Result of Annual General Meeting

All resolutions proposed at the Annual General Meeting held earlier today were duly passed.

Result of General Meeting

All resolutions proposed at the General Meeting held earlier today were duly passed. Following the passing of the resolutions the Company can now proceed with the subdivision of each Existing Ordinary Share of 1p into 10 new Ordinary Shares of 0.1p each (the “Subdivision”) and the placing to raise £1.73 million, before costs, by means of the issue of 34,575,410 new Ordinary Shares at 5 pence per share (the “Placing”) to fund the working capital of the Company.

The Company has made an application to the London Stock Exchange and it is expected that Admission of the new Ordinary Shares and the Placing Shares will take place on 26 July 2011.

Following Admission, the Company will have a single class of shares being Ordinary Shares of 0.1 pence each and there will be 194,093,310 Ordinary Shares in issue, each carrying one vote per Ordinary Share. The Company does not hold any Ordinary Shares in treasury. The total number of voting rights in the Company's Ordinary Shares will be 194,093,310 and this number may be used by shareholders as the denominator in calculations to determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Services Authority's Disclosure and Transparency Rules.

Definitions in this announcement are consistent with those set out in the Circular issued to shareholders of the Company and dated 30 June 2011, a copy of which is available on the Company's website.

Enquiries:

Scancell Holdings Plc Professor Lindy Durrant/Dr Richard Goodfellow + 44 (0)207 245 1100
Hansard Communications Adam Reynolds/Guy McDougall  + 44 (0)207 245 1100
Zeus Capital - Nominated Adviser Ross Andrews/Tom Rowley + 44 (0)161 831 1512

XCAP Securities Plc - Broker

John Belliss/Parimal Kumar       +44 (0) 207 101 7070

Scancell develops new vaccine for the treatment of lung cancer

Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer vaccines, announces that a treatment utilising a DNA vaccine based on its ImmunoBody® technology, in combination with Homspera®, an adjuvant developed by ImmuneRegen BioSciences, Inc.® has produced encouraging anti-tumour results in animal models.

The vaccine, known as SCIB2, stimulates immune responses to the lung cancer antigen NY-ESO-1 and may also have potential utility in oesophageal, liver, gastric, prostate, ovarian and bladder cancers. Unlike classical adjuvants, Homspera® did not enhance the SCIB2 systemic immune response but did make it more effective at the tumour site. This could have profound implications for cancer vaccine therapy.

Scancell is currently conducting a Phase I clinical trial utilising its SCIB1 vaccine which is being developed for the treatment of melanoma. SCIB1 is a novel DNA vaccine which is also being developed using Scancell’s patented ImmunoBody® technology. ImmunoBody® vaccines generate the high-avidity T-cells that kill cancer cells.

ImmuneRegen’s Homspera® has previously been found to synergise with SCIB1 in an animal model. Additionally, previous studies have demonstrated efficacy of Homspera® in enhancing immune responses to infectious disease vaccines, such as influenza.

Professor Lindy Durrant, Chief Executive Officer of Scancell, commented:

“These are outstanding results for Scancell and a significant milestone for the Company. The successful application of Scancell’s ImmunoBody® technology, in conjunction with Homspera®, provides further evidence that our ImmunoBody® vaccine has the potentially groundbreaking ability to augment the immune responses necessary to destroy cancer. We are delighted to be combining our efforts with ImmuneRegen and look forward to progressing our work further at this pivotal moment for Scancell. Shareholders will be kept fully updated with this significant breakthrough. In addition to this highly positive news, we have a number of other promising vaccine candidates in development, which we hope will be the subject of further announcements in due course”.

Hal Siegel Ph.D., Chief Scientific Officer of ImmuneRegen, commented:

“We are very pleased with our ongoing collaboration with Scancell and the results of their studies with Homspera® in conjunction with their ImmunoBody® technology. This is further evidence of the immunostimulatory activity of our compound, and also demonstrates a broader anti-tumour effect than previously reported. Furthermore, these recent studies suggest a specificity regarding the dendritic cell activity of Homspera that is both intriguing and promising. We are anticipating additional studies at Scancell will provide further insights into the activity and value of Homspera as an ImmunoBody® vaccine adjuvant for a potentially broad spectrum of therapeutic cancer treatments.”

ImmuneRegen BioSciences, Inc.® is a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC BB:IRBS.OB)

For further information contact:

Scancell Holdings Plc
Professor Lindy Durrant
+ 44 (0)207 245 1100

Hansard Communications
Adam Reynolds/Guy McDougall
+ 44 (0)207 245 1100

Zeus Capital - Nominated Adviser
Ross Andrews/Tom Rowley
+ 44 (0)161 831 1512

XCAP Securities Plc - Broker
John Belliss/Parimal Kumar
+44 (0)207 101 7070

About Scancell

Scancell is developing novel therapeutic vaccines for the treatment of cancer and infectious diseases based on its groundbreaking ImmunoBody® technology platform. Scancell’s first cancer vaccine SCIB1, which entered clinical trials in 2010, is being developed for the treatment of melanoma.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be administered to a patient, stimulating an immune response. Effective cancer vaccines need to target dendritic cells to stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they cannot specifically target dendritic cells in vivo. Several groups have demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing them with tumour antigens and re-infusing them. However, this procedure is patient specific, time consuming and expensive. Scancell has developed its breakthrough patent protected ImmunoBody® technology to overcome these limitations.

An ImmunoBody® is a human antibody or fusion protein engineered to express helper cell and CTL epitopes from tumour antigens over-expressed by cancer cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour antigens as they have long half-lives and can effectively target dendritic cells via their Fc receptors, allowing efficient stimulation of both helper and CTL responses.

The Immunobody® technology can be adapted to provide the basis for treating any tumour type and may also be of potential utility in the development of vaccines against hepatitis, HIV and other chronic infectious diseases.

Change of Board Structure

Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer vaccines, announces that Dr Richard Goodfellow has been appointed Joint Chief Executive Officer as the Company enters the next phase of its development.  The Board recognises that Dr Goodfellow’s position has evolved into a separate leadership role from that held by Professor Lindy Durrant, including the management of Scancell’s commercial activities, investor and City liaison and management of the Company’s exit strategy.

David Evans, Chairman, commented:

“The Board recognises Richard’s skills and endeavours as being distinct and separate from Lindy’s. He continues to show exceptional leadership built on hard work and a passion to drive shareholder value.”

For further information contact:

Scancell Holdings Plc
Professor Lindy Durrant/Dr Richard Goodfellow
+ 44 (0)207 245 1100

Hansard Communications
Adam Reynolds/Guy McDougall
+ 44 (0)207 245 1100

Zeus Capital - Nominated Adviser
Ross Andrews/Tom Rowley
+ 44 (0)161 831 1512

XCAP Securities Plc - Broker
John Belliss/Parimal Kumar
+44 (0) 207 101 7070

About Scancell
Scancell is developing novel therapeutic vaccines for the treatment of cancer and infectious diseases based on its groundbreaking ImmunoBody® technology platform. Scancell’s first cancer vaccine SCIB1, which entered clinical trials in 2010, is being developed for the treatment of melanoma.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be administered to a patient, stimulating an immune response. Effective cancer vaccines need to target dendritic cells to stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they cannot specifically target dendritic cells in vivo. Several groups have demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing them with tumour antigens and re-infusing them. However, this procedure is patient specific, time consuming and expensive. Scancell has developed its breakthrough patent protected ImmunoBody® technology to overcome these limitations.

An ImmunoBody® is a human antibody or fusion protein engineered to express helper cell and CTL epitopes from tumour antigens over-expressed by cancer cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour antigens as they have long half-lives and can effectively target dendritic cells via their Fc receptors, allowing efficient stimulation of both helper and CTL responses.

The Immunobody® technology can be adapted to provide the basis for treating any tumour type and may also be of potential utility in the development of vaccines against hepatitis, HIV and other chronic infectious diseases.